• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Nature reviews. Urology >T1 bladder cancer: current considerations for diagnosis and management
【24h】

T1 bladder cancer: current considerations for diagnosis and management

机译：T1膀胱癌：诊断和管理的当前考虑因素

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Stage T1 bladder cancers invade the lamina propria of the bladder and, despite sharing many of the genetic features of muscle-invasive bladder cancers, are classified as non-muscle-invasive or 'superficial' tumours. Yet, patients with T1 bladder cancer have an overall mortality of 33% and a cancer-specific mortality of 14% at three years after diagnosis, suggesting that these patients have a high risk of progression and, accordingly, require meticulous surgery, endoscopic surveillance and clinical decision-making. We hypothesize that the variability in the outcomes of patients with T1 bladder cancer is a result of both tumour heterogeneity and pathological staging, as well as inconsistencies in risk stratification, endoscopic resection and schedules of delivery of BCG. Owing to limitations in clinical staging, patients with T1 bladder cancer are at risk of both undertreatment with persistent use of BCG despite recurrence, and overtreatment with early cystectomy. Understanding the molecular features of T1 bladder cancers and how they respond to BCG therapy could improve biomarkers for risk stratification to align therapy with biological risk.
机译：阶段T1膀胱癌侵入膀胱的Lamina Propria，尽管分享了肌肉侵入性膀胱癌的许多遗传特征，被归类为非肌肉侵入性或“肤浅”肿瘤。然而，T1膀胱癌的患者在诊断后三年内的总体死亡率为33％，癌症特异性死亡率为14％，表明这些患者具有很高的进展风险，因此需要细致的手术，内窥镜监测和临床决策。我们假设T1膀胱癌患者结果的变异是肿瘤异质性和病理分期的结果，以及风险分层的不一致，内镜切除和递送BCG的时间表。由于临床分期的局限性，尽管复发，并且早期膀胱切除术，患有T1膀胱癌的患者患有持续使用BCG的患者。了解T1膀胱癌的分子特征以及它们如何应对BCG治疗可以改善生物标志物的风险分层，以使生物风险对准治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号